Home » Authors » Holland Johnson

Articles by Holland Johnson

Panel eyes future uses of diagnostics

Feb. 1, 2004

By Holland Johnson

Focusing on need for new medical technology & getting it to market

Nov. 1, 2003

By Holland Johnson

Two firms take aim at cryotherapy approach to treatment of AF

Oct. 1, 2003

By Holland Johnson

Necessity drives new use for CardioTech's synthetic graft

Sep. 1, 2003

By Holland Johnson

Guidant, Medtronic report cardiac stent development gains

Aug. 1, 2003

By Holland Johnson

Cordis is first to get U.S. approval for its drug-eluting stent

May 1, 2003

By Holland Johnson

Northfield Gets FDA Approval For Phase III Trial Of PolyHeme

March 7, 2003

By Holland Johnson

Northfield Gets FDA Approval For Phase III Trial Of PolyHeme

March 7, 2003

By Holland Johnson

Study: Similar costs for pumps, transplants

Jan. 1, 2003

By Holland Johnson

Study: No downside seen to ICDs trying pacing prior to shock

June 1, 2002

By Holland Johnson

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.